Inositol hexakisphosphate kinase

Inositol hexakisphosphate kinases (IP6Ks) catalyze the conversion of inositol hexakisphosphate (InsP6) into the high-energy pyrophosphate 5-IP7, thereby modulating intracellular phosphate homeostasis and energy metabolism^[1][2][3]. Mechanistically, IP6Ks regulate phosphate export via interaction with the SPX domain of the phosphate transporter XPR1, influencing cellular ATP levels and phosphate flux^[1]. Among the three mammalian isoforms, IP6K1 exhibits unique control over metabolic processes, including insulin signaling inhibition in adipose tissue and promotion of high-fat diet-induced hyperinsulinemia, whereas IP6K2 and IP6K3 have distinct tissue-specific expression and functional profiles^[2][3][4]. In immune cells, IP6K1 limits phosphatidylinositol-(3,4,5)-trisphosphate signaling, thereby modulating neutrophil chemotaxis, phagocytosis, and NADPH oxidase activity, with pharmacological inhibition enhancing these responses^[5]. In the central nervous system, IP6Ks contribute to synaptic vesicle recycling, Akt/GSK3 signaling, neuronal migration, autophagy, and nuclear translocation, implicating them in behavioral and developmental outcomes^[6][4]. Compared with related isoforms, IP6K1 and IP6K3 differentially affect exocytosis and endocytosis of vesicular glutamate transporters, indicating isoform-specific roles in neurotransmission^[6]. Experimental studies employing the pan-IP6K inhibitor TNP have demonstrated the ability to ameliorate metabolic dysfunctions, including obesity, insulin resistance, and fatty liver, highlighting therapeutic potential^[2]. Collectively, these findings emphasize IP6Ks as critical regulators of phosphate and energy homeostasis, immune function, neural signaling, and metabolic disease models^[3][4].